Watson Pharmaceuticals Invests in $15M New Jersey Expansion
"Over the past year, we have outgrown our current administrative headquarters site, as our U.S. and global business has rapidly grown," said Paul Biscaro, Watson president and CEO. "This new facility will ensure that we have a single location for the leadership and shared services functions that are driving our global growth."
New Jersey's Business Employment Incentive Program (BEIP) has extended Watson a grant of approximately $7.3 million over the next 10 years from the state's Economic Development Authority. It has also been approved for a $290,000 Business Retention and Relocation Assistance Grant (BRRAG) to retain 200 jobs in New Jersey.
Watson was the country's third largest producer of generic drugs in 2009 based on prescriptions dispensed. It specializes in drugs for urology and women's health.
French-Based Advanced Accelerator Applications Plans Cancer Drug Production Campus in Indianapolis, Indiana
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
Finding Talent in a Time of Economic Change
Mid-size Markets Competing for Business and Winning
Hitting the Reset Button: How to Pivot the Perception of Economic Development
Innovation in America Reaches New Heights
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019